97 related articles for article (PubMed ID: 1771885)
21. An anesthetized model of lethal canine galactosamine fulminant hepatic failure.
Sielaff TD; Hu MY; Rollins MD; Bloomer JR; Amiot B; Hu WS; Cerra FB
Hepatology; 1995 Mar; 21(3):796-804. PubMed ID: 7875678
[TBL] [Abstract][Full Text] [Related]
22. Side effects and complications. Extended-release high-dose niacin helps lower lipid levels.
TreatmentUpdate; 2005 Dec; 17(7):7-8. PubMed ID: 17225322
[No Abstract] [Full Text] [Related]
23. Hepatotoxicity associated with sustained-release niacin.
Dalton TA; Berry RS
Am J Med; 1992 Jul; 93(1):102-4. PubMed ID: 1626557
[TBL] [Abstract][Full Text] [Related]
24. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
25. Comment: adverse-effect profile of sustained-release niacin.
Jungnickel PW; Maloley PA
DICP; 1991 Sep; 25(9):1014-5. PubMed ID: 1949965
[No Abstract] [Full Text] [Related]
26. The critically ill liver patient: fulminant hepatic failure.
McGuire BM
Semin Gastrointest Dis; 2003 Jan; 14(1):39-42. PubMed ID: 12610854
[TBL] [Abstract][Full Text] [Related]
27. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
[TBL] [Abstract][Full Text] [Related]
28. Niacin and hepatic failure.
Knopp RH
Ann Intern Med; 1989 Nov; 111(9):769. PubMed ID: 2802441
[No Abstract] [Full Text] [Related]
29. Hepatic toxicity of unmodified and time-release preparations of niacin.
Rader JI; Calvert RJ; Hathcock JN
Am J Med; 1992 Jan; 92(1):77-81. PubMed ID: 1731514
[TBL] [Abstract][Full Text] [Related]
30. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
31. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators.
Donaldson BW; Gopinath R; Wanless IR; Phillips MJ; Cameron R; Roberts EA; Greig PD; Levy G; Blendis LM
Hepatology; 1993 Dec; 18(6):1370-6. PubMed ID: 8244261
[TBL] [Abstract][Full Text] [Related]
32. Safety and side effects of sustained-release niacin.
Lavie CJ; Milani RV
JAMA; 1994 Aug; 272(7):513-4; author reply 514-5. PubMed ID: 8046796
[No Abstract] [Full Text] [Related]
33. Fulminant hepatic failure.
Trivedi DR; Shenoy CK; Deodhar KP; Bhalerao VR; Bhalerao RA
J Indian Med Assoc; 1974 Aug; 63(4):122-5. PubMed ID: 4436565
[No Abstract] [Full Text] [Related]
34. [Fulminant liver failure with a fatal outcome due to flutamide].
Fernández Peña CM; Morano Amado LE; Montes Santiago J; Fachal C
Med Clin (Barc); 1997 Feb; 108(6):237-8. PubMed ID: 9102495
[No Abstract] [Full Text] [Related]
35. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.
Insull W; McGovern ME; Schrott H; Thompson P; Crouse JR; Zieve F; Corbelli J
Arch Intern Med; 2004 May; 164(10):1121-7. PubMed ID: 15159270
[TBL] [Abstract][Full Text] [Related]
36. Managing lipid disorders.
Becker G
Iowa Med; 1990 Apr; 80(4):207. PubMed ID: 2335469
[No Abstract] [Full Text] [Related]
37. Fulminant hepatic failure due to allopurinol.
Raper R; Ibels L; Lauer C; Barnes P; Lunzer M
Aust N Z J Med; 1984 Feb; 14(1):63-5. PubMed ID: 6590011
[TBL] [Abstract][Full Text] [Related]
38. Safety and side effects of sustained-release niacin.
Keenan JM; Ripsin CM; Huang Z; McCaffrey DJ
JAMA; 1994 Aug; 272(7):513; author reply 514-5. PubMed ID: 8046795
[No Abstract] [Full Text] [Related]
39. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin.
Etchason JA; Miller TD; Squires RW; Allison TG; Gau GT; Marttila JK; Kottke BA
Mayo Clin Proc; 1991 Jan; 66(1):23-8. PubMed ID: 1988755
[TBL] [Abstract][Full Text] [Related]
40. Safety and side effects of sustained-release niacin.
Shields M; Beckmann SL
JAMA; 1994 Aug; 272(7):514; author reply 514-5. PubMed ID: 8046797
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
